Skip to Main Content

During Tuesday’s Senate hearing on drug pricing, each of the seven pharma execs insisted their companies have never withheld samples from generic rivals, a step that has raised concerns about unfairly thwarting competition. This is because generic companies need samples to develop copycat medicines and, sometimes, run tests to show a product is bioequivalent in order to win regulatory approval.

Yet a recent Food and Drug Administration list of drug makers that withheld samples includes two companies  — Pfizer (PFE) and AstraZeneca (AZN) — whose chief executives testified samples were, in fact, not withheld.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.